newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

TVRD
  • Tvardi Therapeutics reported topline results for next-generation STAT3 inhibitor TTI-109 in healthy volunteers, confirming its prodrug design, improved tolerability, & pharmacodynamic evidence of target engagement.
  • TTI-109 demonstrated TTI-101-equivalent exposure with reduced cellular & humoral immune cell populations correlated with ulcerative colitis (UC) disease severity.
  • UC was selected as the initial disease indication for TTI-109 due to STAT3's role as a convergent node for immune dysregulation, inflammation, & tissue remodeling.
  • The company announced a KOL webinar featuring Dr. Randy Longman on August 19, 2026, to discuss TTI-109's clinical potential in UC.
  • Research & development expenses for Q2 2026 were $4.0 million, down from $5.8 million in 2025, driven by lower TTI-101 clinical costs offset by higher TTI-109 development costs.
  • General & administrative expenses for Q2 2026 were $2.6 million, down from $3.1 million in 2025, primarily due to lower professional fees related to the April 2025 merger.
  • The company reported a net loss of $6.5 million for the three months ended June 30, 2026, compared to a net income of $4.2 million in the prior-year period.
  • Cash, cash equivalents, & short-term investments totaled $15.8 million as of June 30, 2026, sufficient to fund operations through the third quarter of 2027.
  • TTI-101 Phase 1b/2 hepatocellular carcinoma (HCC) topline data is expected in Q4 2026.
  • Clinical trials for TTI-109 in UC are planned for 2027, pending IND application clearance & additional funding.